{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:44:58Z","timestamp":1784148298482,"version":"3.55.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["381587\/2018-5"],"award-info":[{"award-number":["381587\/2018-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vhri.2023.01.011","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T23:56:57Z","timestamp":1679702217000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R"],"prefix":"10.1016","volume":"36","author":[{"given":"Andr\u00e9 S.","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ferson P. de","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica S.D.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9lia M. de A.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya V.M. de S.","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica V.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.vhri.2023.01.011_bib1","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.2007.15.4393","article-title":"Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?","volume":"26","author":"Caligaris-Cappio","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.1.399","article-title":"B-cell chronic lymphocytic leukemia: a bird of a different feather","volume":"17","author":"Caligaris-Cappio","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.vhri.2023.01.011_bib3","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib4","article-title":"Chronic lymphoid leukemia pathogenesis","volume":"27","author":"Garicochea","year":"2005","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"11","key":"10.1016\/j.vhri.2023.01.011_bib5","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib6","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"16","key":"10.1016\/j.vhri.2023.01.011_bib7","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia","volume":"333","author":"Rozman","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","article-title":"A\u00a0network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia","volume":"41","author":"Ladyzynski","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bjhh.2016.07.004","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia","volume":"38","author":"Rodrigues","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.vhri.2023.01.011_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarf\u00f2","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib11","article-title":"Chronic lymphocytic leukemia: a new vision of an old disease (II Brazilian Consensus Meeting on CLL-B)","volume":"27","author":"Chiattone","year":"2005","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"8","key":"10.1016\/j.vhri.2023.01.011_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.vhri.2023.01.011_bib13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib15","article-title":"Epidemiology of chronic lymphocytic leukemia and familial chronic lymphocytic leukemia","volume":"27","author":"Yamamoto","year":"2005","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.vhri.2023.01.011_bib16","author":"Howlader"},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib17","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: a population-based study","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.vhri.2023.01.011_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3324\/haematol.2013.101378","article-title":"The clinical significance of patients\u2019 sex in chronic lymphocytic leukemia","volume":"99","author":"Catovsky","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.vhri.2023.01.011_bib19","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1080\/10428190600799888","article-title":"Incidence rates of the major leukemia subtypes among U.S. Hispanics, blacks, and non-Hispanic whites","volume":"47","author":"Matasar","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.vhri.2023.01.011_bib20","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190600555819","article-title":"Sex differences in incidence and outcome of chronic lymphocytic leukemia patients","volume":"47","author":"Molica","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.vhri.2023.01.011_bib21","first-page":"279","article-title":"The clinical and epidemiological burden of chronic lymphocytic leukaemia","volume":"13","author":"Redaelli","year":"2004","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"10.1016\/j.vhri.2023.01.011_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.blre.2014.12.001","article-title":"The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?","volume":"29","author":"Yang","year":"2015","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41598-017-19081-4","article-title":"Racial differences in four leukemia subtypes: comprehensive descriptive epidemiology","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.vhri.2023.01.011_bib24","first-page":"737","article-title":"Treatment outcomes of novel targeted agents in relapse\/refractory chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"8","author":"Chen","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.vhri.2023.01.011_bib25","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.vhri.2023.01.011_bib26","series-title":"Chronic Lymphocytic Leukemia","author":"Hallek","year":"2019"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib27","first-page":"29","article-title":"Somatic mutation in immunoglobulin gene variable region in patients with chronic lymphocytic leukemia and prognostic impact","volume":"8","author":"Pashaei","year":"2017","journal-title":"Basic Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.vhri.2023.01.011_bib28","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib29","first-page":"185","article-title":"Chronic lymphocytic leukemia\/small lymphocytic leukemia, version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib30","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1002\/ajh.25681","article-title":"Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: a nationwide population-based study","volume":"95","author":"Mattsson","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.vhri.2023.01.011_bib31","article-title":"Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia","volume":"11","author":"Bauer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.vhri.2023.01.011_bib32","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2017-07-731588","article-title":"FCR achieves long-term durable remissions in patients with IGHV-mutated CLL","volume":"130","author":"Chai-Adisaksopha","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vhri.2023.01.011_bib33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"66","author":"Cvetkovi\u0107","year":"2006","journal-title":"Drugs"},{"issue":"10232","key":"10.1016\/j.vhri.2023.01.011_bib34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.vhri.2023.01.011_bib35","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2023.01.011_bib36","author":"Murthy"},{"issue":"25","key":"10.1016\/j.vhri.2023.01.011_bib38","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.01.011_bib41","unstructured":"Methodological Guidelines: Economic Evaluation Guideline. Ministry of Health. Available at: http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf. Accessed March 18, 2023."},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vhri.2023.01.011_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1590\/s1679-45082010rb1567","article-title":"Markov Models in health care","volume":"8","author":"Sato","year":"2010","journal-title":"Einstein (S\u00e3o Paulo)"},{"issue":"5","key":"10.1016\/j.vhri.2023.01.011_bib44","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/0272989X05280562","article-title":"Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response","volume":"25","author":"Hawkins","year":"2005","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0272989X16651869","article-title":"Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival\u00a0and Markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"issue":"9747","key":"10.1016\/j.vhri.2023.01.011_bib48","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2023.01.011_bib49","author":"Putter"},{"issue":"11","key":"10.1016\/j.vhri.2023.01.011_bib50","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib52","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"STATA J"},{"key":"10.1016\/j.vhri.2023.01.011_bib53","unstructured":"Mitchell M, Muftakhidinov B, Winchen T, et\u00a0al. Engauge Digitizer software. https:\/\/doi.org\/10.5281\/zenodo.3941227"},{"key":"10.1016\/j.vhri.2023.01.011_bib54","author":"Boyd"},{"issue":"5","key":"10.1016\/j.vhri.2023.01.011_bib55","first-page":"303","article-title":"A\u00a0formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"DuBois","year":"1989","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib56","first-page":"225","article-title":"Estimation of human body surface area from height and weight","volume":"54","author":"Gehan","year":"1970","journal-title":"Cancer Chemother Rep"},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","article-title":"Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults","volume":"93","author":"Haycock","year":"1978","journal-title":"J\u00a0Pediatr"},{"issue":"17","key":"10.1016\/j.vhri.2023.01.011_bib58","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.vhri.2023.01.011_bib59","first-page":"436","article-title":"Not all body surface area formulas are the same, but does it matter?","volume":"2","author":"Faisal","year":"2016","journal-title":"J\u00a0Glob Oncol"},{"key":"10.1016\/j.vhri.2023.01.011_bib60","unstructured":"Brasil. Health Price Databank. http:\/\/bps.saude.gov.br\/login.jsf. Accessed November 8, 2021."},{"issue":"1","key":"10.1016\/j.vhri.2023.01.011_bib61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A\u00a0web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Shemilt","year":"2010","journal-title":"Evid Policy"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/10428194.2011.605918","article-title":"Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia","volume":"53","author":"Hornberger","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.vhri.2023.01.011_bib63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CMAR.S79258","article-title":"Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine","volume":"7","author":"Mandrik","year":"2015","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.vhri.2023.01.011_bib64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vhri.2023.01.011_bib65","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"9","key":"10.1016\/j.vhri.2023.01.011_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14737167.2018.1443810","article-title":"Cost-Effectiveness Thresholds: methods for setting and examples from around the world","volume":"18","author":"Santos","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib68","first-page":"107","article-title":"Cost-effectiveness and budgetary impact of lipegfilgrastim for the reduction of chemotherapy-induced neutropenia in Brazil Custo-benef\u00edcio e impacto or\u00e7ament\u00e1rio do lipegfilgrastim para a redu\u00e7\u00e3o de neutropenia induzida por quimioterapia no Brasil","volume":"10","author":"Szende","year":"2018","journal-title":"J\u00a0Bras Econ Sa\u00fade"},{"key":"10.1016\/j.vhri.2023.01.011_bib69","unstructured":"Costa EP da SR, Arrais Ada R. Costs of donating blood and blood components at a Brazilian public blood center: from donor to recipient. In: II ReDAPTS Meeting. Rio de Janeiro, Brazil: Fiocruz; 2018. https:\/\/www.arca.fiocruz.br\/handle\/icict\/39060"},{"issue":"10","key":"10.1016\/j.vhri.2023.01.011_bib71","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.vhri.2023.01.011_bib72","series-title":"Evaluation of the Safety and Efficacy of Anti-CD20 Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia and Budgetary Impact of the Incorporation of Rituximab in the SUS. Federal University of Minas Gerais","author":"Matos","year":"2021"},{"key":"10.1016\/j.vhri.2023.01.011_bib73","unstructured":"Azevedo B, Carvalho A, Sasse AD. Cost-effectiveness analysis of rituximab associated with fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia under the Brazilian public health system (SUS). In press."},{"issue":"8","key":"10.1016\/j.vhri.2023.01.011_bib74","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.01.011_bib75","doi-asserted-by":"crossref","first-page":"A264","DOI":"10.1016\/S1098-3015(11)71965-9","article-title":"PCN70 Cost-effectiveness analysis of rituximab therapy in patients with untreated chronic lymphocytic leukemia (CLL) in Brazil","volume":"13","author":"Chiattone","year":"2010","journal-title":"Value Health"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2023.01.011_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3310\/hta14suppl2-04","article-title":"The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche","volume":"14","author":"Main","year":"2010","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.vhri.2023.01.011_bib77","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3109\/10428194.2015.1070151","article-title":"Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia","volume":"57","author":"Muller","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.vhri.2023.01.011_bib78","doi-asserted-by":"crossref","first-page":"A270","DOI":"10.1016\/S1098-3015(10)74322-9","article-title":"PCN71 Cost-effectiveness of rituximab combined with fludarabine and cyclophosphamide in previously untreated patients with chronic lymphocytic leukemia in France","volume":"12","author":"Roussel","year":"2009","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40273-013-0125-7","article-title":"Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse","volume":"32","author":"Adena","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib80","first-page":"274","article-title":"[Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia]","volume":"25","author":"Casado","year":"2011","journal-title":"Gac Sanit"},{"issue":"7","key":"10.1016\/j.vhri.2023.01.011_bib81","doi-asserted-by":"crossref","first-page":"A273","DOI":"10.1016\/S1098-3015(10)74339-4","article-title":"PCN88 an economic evaluation of rituximab versus other first-line treatments for patients with chronic lymphocytic leukemia in Poland","volume":"12","author":"Kawalec","year":"2009","journal-title":"Value Health"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2023.01.011_bib82","first-page":"195","article-title":"Cost-effectiveness of treatment with rituximab in previously untreated patients with chronic lymphocytic leukemia in Romania","volume":"95","author":"Lupu","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.vhri.2023.01.011_bib83","unstructured":"Paulden M. Strategic behavior and the cost-effectiveness threshold: A new conceptual model. Institute of Health Economics. Available at: https:\/\/www.ihe.ca\/publications\/theoretical-models-of-the-cost-effectiveness-threshold-value-assessment-and-health-care-system-sustainability. Accessed January 10, 2019."},{"key":"10.1016\/j.vhri.2023.01.011_bib84","series-title":"Opportunity Cost and Social Values in Health Care Resource Allocation [thesis]","author":"Paulden","year":"2016"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib85","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0272989X16662242","article-title":"Determinants of change in the cost-effectiveness threshold","volume":"37","author":"Paulden","year":"2017","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib86","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib87","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1744133116000049","article-title":"Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use","volume":"11","author":"Culyer","year":"2016","journal-title":"Health Econ Policy Law"},{"issue":"2","key":"10.1016\/j.vhri.2023.01.011_bib88","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0047-2727(73)90002-9","article-title":"Critical ratios and efficient allocation","volume":"2","author":"Weinstein","year":"1973","journal-title":"J\u00a0Public Econ"},{"issue":"9","key":"10.1016\/j.vhri.2023.01.011_bib89","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2023.01.011_bib90","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","article-title":"On the estimation of the cost-effectiveness threshold: why, what, how?","volume":"19","author":"Vallejo-Torres","year":"2016","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40273-014-0146-x","article-title":"Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?","volume":"32","author":"Paulden","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib92","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jval.2015.12.018","article-title":"Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy","volume":"19","author":"Becker","year":"2016","journal-title":"Value Health"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.01.011_bib93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-136692","article-title":"A\u00a0prospective economic analysis of Canadian cancer trials group Clc.2\/Alliance A041202: a randomized phase III comparison of bendamustine-rituximab versus ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia","volume":"136","author":"Cheung","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.01.011_bib94","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1182\/blood-2019-123706","article-title":"Cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab in first-line chronic lymphocytic leukemia in the United States","volume":"134","author":"Davids","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.vhri.2023.01.011_bib95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.leukres.2016.09.005","article-title":"Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in the Netherlands","volume":"50","author":"Blommestein","year":"2016","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib96","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40258-017-0321-2","article-title":"Cost-effectiveness analysis of obinutuzumab for previously untreated chronic lymphocytic leukaemia in Portuguese patients who are unsuitable for full-dose fludarabine-based therapy","volume":"15","author":"Paquete","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"10.1016\/j.vhri.2023.01.011_bib97","doi-asserted-by":"crossref","first-page":"A739","DOI":"10.1016\/j.jval.2016.09.2246","article-title":"Cost-effectiveness analysis of gazyvaro in association to chlorambucil for patients with chronic lymphocytic leukemia when full-dose fludarabine is unsuitable in France","volume":"19","author":"Plommet","year":"2016","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.01.011_bib98","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clinthera.2016.02.005","article-title":"Cost-effectiveness of first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable","volume":"38","author":"Soini","year":"2016","journal-title":"Clin Ther"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:03Z","timestamp":1761941703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109923000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":94,"alternative-id":["S2212109923000183"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.01.011","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}